Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551430 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
A Phase 2 study of Metastatic Soft Tissue Sarcoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 4
- Study locations
NCT04551430: Active Phase 2 study of Metastatic Soft Tissue Sarcoma, sponsored by Washington University School of Medicine.
NCT04551430 is a Phase 2 study of Metastatic Soft Tissue Sarcoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 105 participants, below the 131-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04551430, a Phase 2 study of Metastatic Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 4
- Study locations
Study Summary
The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
Primary Outcome
* Response rate = proportion of participants who achieve complete response or partial response * Complete response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * Partial response: At least a 30% decrease in the sum of the diameters of target lesions
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Cabozantinib
Study Locations (4)
California
- Stanford University Medical Center - Stanford
Colorado
- University of Colorado - Aurora
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Abramson Cancer Center at Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What the registry record for NCT04551430 still lists
NCT04551430 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 131-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04551430 reports a single indexed study location in California, Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT04551430 about?
NCT04551430 is a clinical study titled "Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma". The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
What is the current status of trial NCT04551430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2021-01-05. Estimated completion is 2029-02-01.
What conditions does trial NCT04551430 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma.
What interventions are being tested in trial NCT04551430?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04551430?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551430 being conducted?
This trial has 4 study locations across California, Colorado, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04551430's enrollment target sits among peer trials
105 5th of 12 higher than 8 of 12 other Metastatic Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
RECRUITING · Phase 2
-
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
COMPLETED · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI